Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Next Previous
X
Search
Drug Profile

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of California; University of Cologne
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T-cell prolymphocytic leukaemia
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; Lymphoma; Sezary syndrome; T-cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2022 Phase-III development in Multiple sclerosis (In adolescents, In children) is ongoing in Belgium and Netherlands (IV) (NCT03368664)
  • 13 Oct 2021 Updated efficacy and safety data from the phase III CARE-MS 1 follow-up TOPAZ trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
  • 13 Oct 2021 Updated safety and efficacy data from the phase III CARE-MS II trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top